Paired with the PD-1 antibody, blocking siglec-10’s binding to CD24 improved the anti-HCC activity of CD8+ T cells and may synergistically promote tumor apoptosis which were from fresh human specimens with HCC patients (194). Here, CD8A is linked to hepatocellular carcinoma.